Northwest Biotherapeutics, Inc. to Present New Phase I/II Clinical Data On Promising Prostate Cancer Treatment Business Wire; Mar 5, 2002
BOTHELL, Wash.--(BUSINESS WIRE)--March 5, 2002--Northwest Biotherapeutics, Inc. (Nasdaq:NWBT) announced today that it will present favorable results from the Phase I/II late-stage prostate cancer clinical evaluation of its dendritic cell-based immunotherapy, DCVax-Prostate.
The data will be presented at the invitation only, Fourth Walker's Cay Colloquium on Cancer Vaccines and Immunology sponsored by the Albert B. Sabin Vaccine Institute.
The Colloquium will take place March 6-10, 2002 at Walker Cay's private island in the Bahamas where President Nixon made the decision to initiate Cancer Control Month in 1969, leading to his declaration of War on Cancer.
Dr. Michael Salgaller, Northwest Biotherapeutics' Vice President of Clinical and Research affairs, will present data from 29 late-stage prostate cancer patients with no other treatment alternatives who received DCVax-Prostate during a Phase I/II trial conducted at the M.D. Anderson Cancer Center, Houston, and at UCLA.
You wrote, "The Colloquium will take place March 6-10, 2002 at Walker Cay's private island in the Bahamas where President Nixon made the decision to initiate Cancer Control Month in 1969, leading to his declaration of War on Cancer."
Cancer runs in Mr. Nixons family, I know because he is a relative.
Northwest Biotherapeutics observed overall stabilization of disease in 55% (16 of 29) of the patients in its Phase I/II clinical trial. Ten of these patients with rising PSA values following hormone therapy did not have measurable metastatic disease at the time of treatment initiation. All ten were stable at the conclusion of the trial as measured by radiographic criteria at weeks 23 and 28.
A noted urologist, clinical consultant and Northwest Biotherapeutics' cofounder, Dr. Haakon Ragde, stated "although the patient numbers are small, no other treatment methodology he is aware of has had such a measurable positive impact on this patient population."
Dr. Ragde also indicated that Northwest Biotherapeutics recently initiated a 495 patient double blind, placebo-controlled trial to further evaluate DCVax-Prostate for treating late-state prostate cancer patients at 20 to 25 clinical sites in the United States.
About Northwest Biotherapeutics:
Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. The Company combines its expertise in dendritic cell biology, immunology and antigen discovery with its proprietary technologies to develop cancer therapies.
Northwest Biotherapeutics' development efforts are based on two proprietary and versatile approaches - DCVax, a dendritic cell-based immunotherapy platform and HuRx, a fully human monoclonal antibody platform.
The Company's lead DCVax product candidate, DCVax-Prostate, is a prostate cancer treatment that is currently in a pivotal Phase III clinical trial.
It is initiating a multi-site Phase II clinical trial to evaluate DCVax-Brain as a possible treatment for Glioblastoma Multiforme, a lethal form of brain cancer and it recently received FDA clearance to begin a Phase I evaluation of its DCVax-Lung as a potential treatment for lung cancer.
HuRx is a human monoclonal antibody program that is being co-developed with Medarex, Inc. Northwest Biotherapeutics' lead HuRx product candidate, HuRx-Prostate is currently being manufactured for anticipated Phase I clinical trials.
Except for the historical information presented in this news release, matters discussed herein may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.
Factors that might cause such a difference include, but are not limited to, uncertainties related to the progress, costs and results of the Company's clinical trials, progress of research and development projects, and uncertainties related to whether the Company's product candidates would ultimately achieve commercial success in the event that regulatory clearance were received.
Reference should be made to Northwest Biotherapeutics' public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Registration Statement on Form S-1. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release.
Northwest Biotherapeutics disclaims any intent or obligation to update these forward-looking statements to reflect new information, events, or circumstances after the date of this release or to reflect the occurrence of anticipated events. Copies of Northwest Biotherapeutics' public disclosure filings are available from its investor relations department.
DCVax and HuRx are trademarks of Northwest Biotherapeutics, Inc. All rights are reserved.